December 3, 2020

Canexia Health Co-Founder David Hunstman’s exclusive interview with OncLive

Canexia Health's Co-Founder and Chief Medical Officer David Hunstman was recently interviewed by OncLive as part of their OncLive On Air Podcast. In this exclusive interview, Dr. Huntsman discusses the elements of precision medicine that have contributed to its growth in oncology, some of the setbacks regarding its integration, and areas of research that have the potential to propel precision medicine to the next tier of scientific discovery and application.


November 19, 2020

Making the case for bringing precision oncology testing in-house in complex healthcare systems

Developing the business case for bringing cancer testing in-house can be a daunting task for laboratory, pathology, and other scientific professionals. In this presentation, Dr. Gregory Tranah, of Sutter Health, discusses opportunities and challenges that bringing in-house testing to a large, complex, health system presents. Dr. Tranah will discuss critical success factors such as personalization, portability, safety, and accessibility for others who are considering embarking on this path.


November 13, 2020

Liquid Biopsy Offers New Hope for Ontario Family

COVID-19 has created serious challenges for people living with advanced-stage cancer. In response, Canexia Health launched Project ACTT this summer, a federally-funded program to provide liquid biopsy testing to 2,000 patients across Canada with advanced or metastatic breast, lung, and colorectal cancer. Here is one patient’s story.


November 9, 2020

4 Lessons for Late Stage Cancer Care During COVID-19

COVID-19 has had dramatic impacts on all aspects of healthcare, including treatment selection and monitoring of late stage cancers. Last week, Brady Davis, Canexia's SVP of Corporate Development, moderated a workshop on this topic as part of the Association for Molecular Pathology 2020 conference, bringing together four global experts in oncology and pathology.


September 22, 2020

Why Bring Liquid Biopsy Testing In-House? The Case for Millions in Cost Savings

We recently conducted a cost savings analysis for healthcare organizations interested in bringing liquid biopsy testing in-house. We discovered that, compared to outsourcing, in-house liquid biopsy testing with an actionable circulating tumor DNA (ctDNA) panel would enable healthcare organizations to attain substantial cost savings -- $2.7M per 1,000 cancer patients.

In the News

August 27, 2020

DeciBio’s Q&A with Brady Davis, SVP of Business Development for Canexia Health

DeciBio interviewed Canexia Health's Brady Davis to discuss how Canexia Health and Project ACTT (Access to Testing and Treatment) are leveraging Canexia’s tech transfer platform and liquid biopsy test, Follow IT, to bridge the gap between the Canadian cancer community and molecular testing during the COVID-19 pandemic.

More Information at Your Fingertips

Every Canexia Health report comes with therapeutic recommendations based on specific gene mutations and patient profiles, with clinical trials reviewed and selected by certified clinical molecular geneticists.

Learn More